{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:58:06Z","timestamp":1785164286839,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejphar.2021.174452","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T10:48:44Z","timestamp":1630493324000},"page":"174452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset"],"prefix":"10.1016","volume":"910","author":[{"given":"Imane","family":"Frouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Belliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Maddaford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-8334","authenticated-orcid":false,"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis--incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa\u2010induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174452_bib3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/mol.60.6.1414","article-title":"ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter","volume":"60","author":"Atkinson","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2021.174452_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.bjp.0704381","article-title":"N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport","volume":"134","author":"Aubrey","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/ALN.0000000000000203","article-title":"Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats","volume":"121","author":"Barthel","year":"2014","journal-title":"Anesthesiology"},{"issue":"10","key":"10.1016\/j.ejphar.2021.174452_bib6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-020-02247-2","article-title":"The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results","volume":"127","author":"Beaudry","year":"2020","journal-title":"J. Neural. Transm."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1476-5381.2012.01975.x","article-title":"The solute carrier 6 family of transporters","volume":"167","author":"Broer","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.ejphar.2021.174452_bib10","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/npp.2014.4","article-title":"Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates","volume":"39","author":"Castner","year":"2014","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.ejphar.2021.174452_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1152\/jn.00575.2010","article-title":"Nicotinic excitation of serotonergic projections from dorsal raphe to the nucleus accumbens","volume":"106","author":"Chang","year":"2011","journal-title":"J. Neurophysiol."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2021.174452_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01345244","article-title":"Direct and indirect presynaptic control of dopamine release by excitatory amino acids","volume":"14","author":"Cheramy","year":"1998","journal-title":"Amino acids"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1523\/JNEUROSCI.07-02-00357.1987","article-title":"Glutamate neurotoxicity in cortical cell culture","volume":"7","author":"Choi","year":"1987","journal-title":"J. Neurosci."},{"issue":"9916","key":"10.1016\/j.ejphar.2021.174452_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174452_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fpsyt.2020.00369","article-title":"Glycine signaling in the framework of dopamine-glutamate interaction and postsynaptic density. Implications for treatment-resistant schizophrenia","volume":"11","author":"de Bartolomeis","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-013-3260-0","article-title":"The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey","volume":"231","author":"Eddins","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.ejphar.2021.174452_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"issue":"9169","key":"10.1016\/j.ejphar.2021.174452_bib22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174452_bib23","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174452_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1017\/S1461145711001015","article-title":"D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease","volume":"15","author":"Gelfin","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2021.174452_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/syn.20966","article-title":"Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1","volume":"65","author":"Gunn","year":"2011","journal-title":"Synapse"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174452_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"13","key":"10.1016\/j.ejphar.2021.174452_bib29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00213-016-4317-7","article-title":"Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers","volume":"233","author":"Hofmann","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"issue":"10","key":"10.1016\/j.ejphar.2021.174452_bib30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174452_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"issue":"19","key":"10.1016\/j.ejphar.2021.174452_bib32","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174452_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Mol. Psychiatr."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174452_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.npp.1300589","article-title":"Modulation of striatal dopamine release by glycine transport inhibitors","volume":"30","author":"Javitt","year":"2005","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0361-9230(00)00258-6","article-title":"Inhibition of striatal dopamine release by glycine and glycyldodecylamide","volume":"52","author":"Javitt","year":"2000","journal-title":"Brain Res. Bull."},{"issue":"4867","key":"10.1016\/j.ejphar.2021.174452_bib37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1126\/science.2841759","article-title":"Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes","volume":"241","author":"Kleckner","year":"1988","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.ejphar.2021.174452_bib38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2021.174452_bib39","doi-asserted-by":"crossref","first-page":"108386","DOI":"10.1016\/j.neuropharm.2020.108386","article-title":"Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset","volume":"182","author":"Kwan","year":"2021","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1523\/JNEUROSCI.13-03-01088.1993","article-title":"Interactions between the glycine and glutamate binding sites of the NMDA receptor","volume":"13","author":"Lester","year":"1993","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174452_bib41","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bcp.12015","article-title":"Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men","volume":"75","author":"Liem-Moolenaar","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/cn100017a","article-title":"GlyT1 - up from the Ashes. The importance of not condemning a mechanism based on a single chemotype","volume":"1","author":"Lindsley","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174452_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0028-3908(03)00227-2","article-title":"Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine","volume":"45","author":"Mallorga","year":"2003","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174452_bib44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/npp.2012.212","article-title":"Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers","volume":"38","author":"Martin-Facklam","year":"2013","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eplepsyres.2007.10.007","article-title":"Seizure activity and changes in hippocampal extracellular glutamate, GABA, dopamine and serotonin","volume":"78","author":"Meurs","year":"2008","journal-title":"Epilepsy Res."},{"issue":"7\u20138","key":"10.1016\/j.ejphar.2021.174452_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/dta.1620","article-title":"From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs","volume":"6","author":"Morris","year":"2014","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","article-title":"Safety, tolerability and pharmacokinetics of oral BI 425809, a Glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study","volume":"43","author":"Moschetti","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0168-0102(02)00027-5","article-title":"Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway","volume":"43","author":"Nambu","year":"2002","journal-title":"Neurosci. Res."},{"issue":"13","key":"10.1016\/j.ejphar.2021.174452_bib49","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.ejphar.2021.174452_bib50","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.ejphar.2021.174452_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaneurol.2017.3205","article-title":"ADS-5102 (amantadine) extended release for levodopa-induced dyskinesia","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174452_bib52","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res Brain Res Rev"},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0165-0173(94)00008-D","article-title":"Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res Brain Res Rev"},{"issue":"10","key":"10.1016\/j.ejphar.2021.174452_bib55","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174452_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural. Transm."},{"issue":"5","key":"10.1016\/j.ejphar.2021.174452_bib57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.neuropharm.2008.06.016","article-title":"Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas","volume":"55","author":"Perry","year":"2008","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.ejphar.2021.174452_bib58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine (Symmetrel)","volume":"23","author":"Postma","year":"1975","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"issue":"2A","key":"10.1016\/j.ejphar.2021.174452_bib60","first-page":"265","article-title":"Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia","volume":"42","author":"Riederer","year":"1992","journal-title":"Arzneimittelforschung"},{"issue":"42","key":"10.1016\/j.ejphar.2021.174452_bib61","doi-asserted-by":"crossref","first-page":"16778","DOI":"10.1523\/JNEUROSCI.3041-12.2013","article-title":"Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons","volume":"33","author":"Schmitz","year":"2013","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0000000000000073","article-title":"The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial","volume":"34","author":"Schoemaker","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2021.174452_bib63","doi-asserted-by":"crossref","first-page":"172957","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"873","author":"Sid-Otmane","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.ejphar.2021.174452_bib65","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174452_bib66","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nucmedbio.2010.11.009","article-title":"In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys","volume":"38","author":"Toyohara","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejphar.2021.174452_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/pcn.12175","article-title":"Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia","author":"Tsai","year":"2014","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.ejphar.2021.174452_bib68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.ejphar.2021.174452_bib69","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174452_bib70","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174452_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"\u03b11-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174452_bib72","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"issue":"Pt 13","key":"10.1016\/j.ejphar.2021.174452_bib73","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1113\/jphysiol.2009.168757","article-title":"The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine","volume":"587","author":"Zhang","year":"2009","journal-title":"J. Physiol."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2021.174452_bib74","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2003.08.065","article-title":"Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets","volume":"993","author":"Zhang","year":"2003","journal-title":"Brain Res."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2021.174452_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01345243","article-title":"Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum","volume":"14","author":"Zigmond","year":"1998","journal-title":"Amino Acids"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:16:46Z","timestamp":1762143406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":75,"alternative-id":["S0014299921006063"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174452","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174452"}}